ADVISORY/Daniel B. Yarosh, Ph.D., President of AGI Dermatics, is presenting the results of their clinical study on prevention of skin cancer before the Photomedicine Society, meeting in conjunction with the American Academy of Dermatology.

News Editors/Health & Medical Writers

ADVISORY...for Thursday (March 1)

--(BW HealthWire)

Who:    Daniel B. Yarosh, Ph.D., President of AGI Dermatics, is
        presenting the results of their clinical study on prevention
        of skin cancer before the Photomedicine Society, meeting in
        conjunction with the American Academy of Dermatology.

What:   T4N5 Liposomes Lotion (tradename Dimericine(tm)) is the lead
        drug of AGI Dermatics the clinical results shows that it
        prevents skin cancer.

When:   11:30 am, Thursday, March 1, 2001

Where:  PhotoMedicine Society meeting at the Washington DC Renaissance
        Hotel, 999 9th St NW, Ballroom West B.

Why:    Dr. Yarosh will present for the first time the results of a
        clinical study showing prevention of skin cancer by a new
        biotechnology drug. The drug is applied topically to the skin,
        once and day, and uses liposomes to deliver DNA repair enzymes
        into the skin that reverse the DNA damage caused by sunlight.
        In a one-year study of patients with the genetic disease
        xeroderma pigmentosum, who lack DNA repair and easily develop
        skin cancer, the drug reduced skin cancer by 30% and reduced a
        pre-cancerous form by 68%, over and above the protection from
        sunscreens. This topical lotion is a new approach to
        preventing skin cancer in all people damaged by sunlight. Dr.
        David Leffell, a Yale University Dermatologist, calls this
        "the biggest advance since sunscreens."

Interview opportunity: Interviews may be arranged prior to the meeting by request, or following the meeting.